FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134273037> ?p ?o ?g. }

• W2134273037 endingPage "1215" @default.
• W2134273037 startingPage "1210" @default.
• W2134273037 abstract "Purpose To investigate whether American Joint Committee on Cancer (AJCC) classification at initial diagnosis of lacrimal gland adenoid cystic carcinoma predicts outcome of treatment on local recurrence. Design Retrospective chart review. Participants Consecutive patients with adenoid cystic carcinoma of the lacrimal gland treated at 8 institutions between January 1986 and December 2007. Methods Clinical records, including pathology reports and imaging studies, were reviewed. Main Outcome Measures AJCC classification, histologic subtype, local recurrence rate, and survival. Results AJCC classification at initial diagnosis was assessable for 53 patients and was as follows: T1N0M0, 7 patients; T2N0M0, 8 patients; T3aN0M0, 14 patients; T3aNxM0, 1 patient; T3aN0M1, 1 patient; T3bN0M0, 13 patients; T3bN0M1, 1 patient; T4aN0M0, 2 patients; T4bN0M0, 4 patients; T4bN0M1, 1 patient; and T4bNXM0, 1 patient. Thirty-eight (72%) of the 53 patients had >T3 tumors at presentation. Of the 38 patients with >T3 tumors, 20 were treated with orbital exenteration and postoperative adjuvant radiotherapy (RT), 6 were treated with orbital exenteration without RT, and 12 were treated with globe-preserving surgery (10 with RT and 2 without RT). Of the 15 patients with <T3 tumors, 6 were treated with globe-preserving surgery and RT, 2 were treated with globe-preserving surgery without RT, 6 were treated with orbital exenteration with bone removal and RT, and 1 was treated with orbital exenteration with bone removal without RT. Only 1 patient with a <T3 tumor, had local recurrence. Among patients with >T3 tumors, the risk of local recurrence (in the orbit or skull base) was higher in patients treated with conservative surgery as opposed to orbital exenteration and RT. Only 4 (20%) of the 20 patients treated with orbital exenteration and RT had local recurrence, compared with 3 (50%) of the 6 patients treated with orbital exenteration without RT and 8 (67%) of the 12 patients treated with globe-preserving surgery. Overall, 17 (45%) of the 38 patients with >T3 tumors and only 1 (7%) of the 15 patients with <T3 tumors died of disease during the study period. Conclusions In patients with lacrimal gland adenoid cystic carcinoma, AJCC >T3 disease at initial diagnosis correlates with worse outcomes than does AJCC <T3 disease. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To investigate whether American Joint Committee on Cancer (AJCC) classification at initial diagnosis of lacrimal gland adenoid cystic carcinoma predicts outcome of treatment on local recurrence. Retrospective chart review. Consecutive patients with adenoid cystic carcinoma of the lacrimal gland treated at 8 institutions between January 1986 and December 2007. Clinical records, including pathology reports and imaging studies, were reviewed. AJCC classification, histologic subtype, local recurrence rate, and survival. AJCC classification at initial diagnosis was assessable for 53 patients and was as follows: T1N0M0, 7 patients; T2N0M0, 8 patients; T3aN0M0, 14 patients; T3aNxM0, 1 patient; T3aN0M1, 1 patient; T3bN0M0, 13 patients; T3bN0M1, 1 patient; T4aN0M0, 2 patients; T4bN0M0, 4 patients; T4bN0M1, 1 patient; and T4bNXM0, 1 patient. Thirty-eight (72%) of the 53 patients had >T3 tumors at presentation. Of the 38 patients with >T3 tumors, 20 were treated with orbital exenteration and postoperative adjuvant radiotherapy (RT), 6 were treated with orbital exenteration without RT, and 12 were treated with globe-preserving surgery (10 with RT and 2 without RT). Of the 15 patients with <T3 tumors, 6 were treated with globe-preserving surgery and RT, 2 were treated with globe-preserving surgery without RT, 6 were treated with orbital exenteration with bone removal and RT, and 1 was treated with orbital exenteration with bone removal without RT. Only 1 patient with a <T3 tumor, had local recurrence. Among patients with >T3 tumors, the risk of local recurrence (in the orbit or skull base) was higher in patients treated with conservative surgery as opposed to orbital exenteration and RT. Only 4 (20%) of the 20 patients treated with orbital exenteration and RT had local recurrence, compared with 3 (50%) of the 6 patients treated with orbital exenteration without RT and 8 (67%) of the 12 patients treated with globe-preserving surgery. Overall, 17 (45%) of the 38 patients with >T3 tumors and only 1 (7%) of the 15 patients with <T3 tumors died of disease during the study period. In patients with lacrimal gland adenoid cystic carcinoma, AJCC >T3 disease at initial diagnosis correlates with worse outcomes than does AJCC <T3 disease." @default.
• W2134273037 created "2016-06-24" @default.
• W2134273037 creator A5005949106 @default.
• W2134273037 creator A5009059827 @default.
• W2134273037 creator A5019368710 @default.
• W2134273037 creator A5029393091 @default.
• W2134273037 creator A5045341937 @default.
• W2134273037 creator A5049479098 @default.
• W2134273037 creator A5053253191 @default.
• W2134273037 creator A5056116473 @default.
• W2134273037 creator A5056915588 @default.
• W2134273037 creator A5071699571 @default.
• W2134273037 creator A5076491232 @default.
• W2134273037 creator A5080939187 @default.
• W2134273037 creator A5081221013 @default.
• W2134273037 creator A5084715257 @default.
• W2134273037 date "2009-06-01" @default.
• W2134273037 modified "2023-10-17" @default.
• W2134273037 title "American Joint Committee on Cancer Classification Predicts Outcome of Patients with Lacrimal Gland Adenoid Cystic Carcinoma" @default.
• W2134273037 cites W1970069263 @default.
• W2134273037 cites W1972121227 @default.
• W2134273037 cites W1974049542 @default.
• W2134273037 cites W1974913817 @default.
• W2134273037 cites W2000161070 @default.
• W2134273037 cites W2005175510 @default.
• W2134273037 cites W2007316943 @default.
• W2134273037 cites W2007918090 @default.
• W2134273037 cites W2017035167 @default.
• W2134273037 cites W2018151955 @default.
• W2134273037 cites W2031052594 @default.
• W2134273037 cites W2034114186 @default.
• W2134273037 cites W2036589190 @default.
• W2134273037 cites W2047395460 @default.
• W2134273037 cites W2055426184 @default.
• W2134273037 cites W2057726484 @default.
• W2134273037 cites W2069445485 @default.
• W2134273037 cites W2072864341 @default.
• W2134273037 cites W2076347049 @default.
• W2134273037 cites W2077004530 @default.
• W2134273037 cites W2082465904 @default.
• W2134273037 cites W2105267848 @default.
• W2134273037 cites W2157117983 @default.
• W2134273037 cites W376488926 @default.
• W2134273037 doi "https://doi.org/10.1016/j.ophtha.2008.12.049" @default.
• W2134273037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19395039" @default.
• W2134273037 hasPublicationYear "2009" @default.
• W2134273037 type Work @default.
• W2134273037 sameAs 2134273037 @default.
• W2134273037 citedByCount "108" @default.
• W2134273037 countsByYear W21342730372012 @default.
• W2134273037 countsByYear W21342730372013 @default.
• W2134273037 countsByYear W21342730372014 @default.
• W2134273037 countsByYear W21342730372015 @default.
• W2134273037 countsByYear W21342730372016 @default.
• W2134273037 countsByYear W21342730372017 @default.
• W2134273037 countsByYear W21342730372018 @default.
• W2134273037 countsByYear W21342730372019 @default.
• W2134273037 countsByYear W21342730372020 @default.
• W2134273037 countsByYear W21342730372021 @default.
• W2134273037 countsByYear W21342730372022 @default.
• W2134273037 countsByYear W21342730372023 @default.
• W2134273037 crossrefType "journal-article" @default.
• W2134273037 hasAuthorship W2134273037A5005949106 @default.
• W2134273037 hasAuthorship W2134273037A5009059827 @default.
• W2134273037 hasAuthorship W2134273037A5019368710 @default.
• W2134273037 hasAuthorship W2134273037A5029393091 @default.
• W2134273037 hasAuthorship W2134273037A5045341937 @default.
• W2134273037 hasAuthorship W2134273037A5049479098 @default.
• W2134273037 hasAuthorship W2134273037A5053253191 @default.
• W2134273037 hasAuthorship W2134273037A5056116473 @default.
• W2134273037 hasAuthorship W2134273037A5056915588 @default.
• W2134273037 hasAuthorship W2134273037A5071699571 @default.
• W2134273037 hasAuthorship W2134273037A5076491232 @default.
• W2134273037 hasAuthorship W2134273037A5080939187 @default.
• W2134273037 hasAuthorship W2134273037A5081221013 @default.
• W2134273037 hasAuthorship W2134273037A5084715257 @default.
• W2134273037 hasConcept C121608353 @default.
• W2134273037 hasConcept C126322002 @default.
• W2134273037 hasConcept C141071460 @default.
• W2134273037 hasConcept C142724271 @default.
• W2134273037 hasConcept C167135981 @default.
• W2134273037 hasConcept C2777546739 @default.
• W2134273037 hasConcept C2779231225 @default.
• W2134273037 hasConcept C2779298748 @default.
• W2134273037 hasConcept C509974204 @default.
• W2134273037 hasConcept C71924100 @default.
• W2134273037 hasConceptScore W2134273037C121608353 @default.
• W2134273037 hasConceptScore W2134273037C126322002 @default.
• W2134273037 hasConceptScore W2134273037C141071460 @default.
• W2134273037 hasConceptScore W2134273037C142724271 @default.
• W2134273037 hasConceptScore W2134273037C167135981 @default.
• W2134273037 hasConceptScore W2134273037C2777546739 @default.
• W2134273037 hasConceptScore W2134273037C2779231225 @default.
• W2134273037 hasConceptScore W2134273037C2779298748 @default.
• W2134273037 hasConceptScore W2134273037C509974204 @default.
• W2134273037 hasConceptScore W2134273037C71924100 @default.
• W2134273037 hasIssue "6" @default.
• W2134273037 hasLocation W21342730371 @default.

• next